Raymond James Maintains Outperform on Cytokinetics, Raises Price Target to $92
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Sean McCutcheon has maintained an Outperform rating on Cytokinetics (NASDAQ:CYTK) and increased the price target from $63 to $92.
December 28, 2023 | 12:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James analyst Sean McCutcheon maintains an Outperform rating on Cytokinetics and raises the price target from $63 to $92, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst firm like Raymond James typically signals a strong conviction in the company's future performance and can lead to increased investor confidence, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100